

**From:** Prof. Philippe Gillery – IFCC SD Chair

**Date:** November 24<sup>th</sup>, 2022

**Ref:** 8.2.27 Call for Nominations for Membership of Committee on Bone Metabolism (C-BM)

## Scientific Division (SD)

### Chair

**Prof. Philippe GILLERY**

Service de Biochimie - Pharmacologie  
- Toxicologie  
Pôle de Biologie Médicale et  
Pathologie  
CHU de Reims  
Pôle de Biologie Territoriale  
51092 Reims Cedex - FRANCE  
E-mail: [pgillery@chu-reims.fr](mailto:pgillery@chu-reims.fr)

### Vice-Chair

**Prof. Christa M. COBBAERT**

Clinical Chemist  
Head of the Department of Clinical Chemistry  
Leiden University Medical Center  
2300 RC Leiden – THE NETHERLANDS  
E-mail: [C.M.Cobbaert@lumc.nl](mailto:C.M.Cobbaert@lumc.nl)

### Secretary

**Prof. Garry JOHN**

Department of Clinical Biochemistry and  
Immunology  
Norfolk and Norwich University Hospital  
Norwich NR4 7UY - UK  
E-mail: [g.john@nhs.net](mailto:g.john@nhs.net)

### Members

**Dr. Barnali DAS**

Lead Consultant, Biochemistry & Immunology  
Kokilaben Dhirubhai Ambani Hospital &  
Medical Research Institute,  
Mumbai-400053 - INDIA  
E-mail: [drbarnalid@gmail.com](mailto:drbarnalid@gmail.com)

**Dr. Konstantinos MAKRI**

Clinical Biochemist  
Clinical Biochemistry Department  
KAT General Hospital  
Kifissia, Athens - GREECE  
E-mail: [kostas.makris.km@gmail.com](mailto:kostas.makris.km@gmail.com)

**Prof. Mario PLEBANI**

Full Professor of Clinical Biochemistry and  
Clinical Molecular Biology  
Chief Department of Laboratory Medicine  
University Hospital – Padova  
Dean of the Medical School  
University of Padova – ITALY  
E-mail: [mario.plebani@unipd.it](mailto:mario.plebani@unipd.it)

### Corporate Representative

**Dr. Michael ROTTMANN**

Roche Diagnostics GmbH  
Director Assay Development  
Indication: Thyroid, Sepsis, RA, Growth Centralised  
and Point of Care solutions  
82377 Penzberg - GERMANY  
e-mail: [michael.rottmann@roche.com](mailto:michael.rottmann@roche.com)

### Bureau International des Poids et Mesures

#### Mesures

#### BIPM Observer

**Dr. Ralf D. JOSEPHS**

Principal Chemist  
Pavillon de Breteuil  
92312 Sèvres Cedex - FRANCE  
E-mail: [ralf.josephs@bipm.org](mailto:ralf.josephs@bipm.org)

### European Commission –

#### JRC Observer

**Dr. Liesbet DEPREZ**

Project Officer  
Directorate General Joint Research Centre  
Reference Materials Unit  
2440 Geel – BELGIUM  
E-mail: [Liesbet.deprez@ec.europa.eu](mailto:Liesbet.deprez@ec.europa.eu)

### ICHCLR Observer

**Prof. Ian S. YOUNG**

Professor of Medicine  
Queen's University Belfast  
The Center for Public Health  
1st floor - ICS B block  
Royal Victoria Hospital  
BT12 6BJ - Belfast - UK  
E-mail: [I.Young@qub.ac.uk](mailto:I.Young@qub.ac.uk)

### JCTLM Consultant

**Dr. Greg MILLER**

Professor of Pathology  
Co-Director of Clinical Chemistry  
Director of Pathology Information Systems  
Virginia Commonwealth University Health System  
Richmond, VA 23298-0286 - USA  
Email: [greg.miller@vcuhealth.org](mailto:greg.miller@vcuhealth.org)

### NIBSC Consultant

**Dr. Chris BURNS PhD**

Head, Biotherapeutics Division  
National Institute for Biological Standards and  
Control - A Centre of the MHRA  
Hertfordshire, EN6 3QG, UK  
E-mail: [Chris.Burns@nibsc.org](mailto:Chris.Burns@nibsc.org)

### NIFDC Observer

**Dr. Yang Zhen**

Deputy Director General  
National Institutes for Food and Drug Controls  
(NIFDC) - P.R. CHINA  
E-mail: [yangzhen@nifdc.org.cn](mailto:yangzhen@nifdc.org.cn)

### NIST Consultant

**Dr. Karen W. PHINNEY**

Leader, Bioanalytical Science Group  
Biomolecular Measurement Division  
National Institute of Standards  
and Technology (NIST)  
Gaithersburg, MD 20899-8314 - USA  
E-mail: [karen.phinney@nist.gov](mailto:karen.phinney@nist.gov)

**To: IFCC Full Member Societies' National Representatives  
IFCC Affiliate Societies' Representatives  
IFCC Corporate Members' Representatives**

Dear Colleagues,

In January 2019 the IFCC created a Committee on “Bone Metabolism (C-BM)”, formed by the joining of the already existing Working Groups:

The terms of reference and current projects of the C-BM are as follows:

- Standardization of Bone Markers Assays (WG-BMA) in collaboration with IOF
- Parathyroid Hormone (WG-PTH)
- Vitamin D Standardization Program (WG-Vit D)

The C-BM under the Chairmanship of *Prof. Etienne Cavalier*, Head of the Department of Clinical Chemistry at the University of Liège ([etienne.cavalier@chu.ulg.ac.be](mailto:etienne.cavalier@chu.ulg.ac.be)), intends to replace one member, whose time in office will begin in January 2023 for a 3 years' term (ending December 2025). A second three-year term is allowed following satisfactory review at the end of the first term by the Scientific Division Executive Committee following consultation with the C-BM Chairman. We would particularly welcome applications from young scientists and candidates with experience in metrological, analytical and clinical aspects of evaluation of bone metabolism markers, although all applications will be given careful consideration.

The C-BM Current Projects are as follows:

### 1. PTH assays

- Create liaison with International Endocrinological, Rheumatological and Nephrological organizations
- Define the measurand (what we need to measure for all clinical situations)
- Develop a reference measurement procedure for PTH(1-84) and moieties of clinical interest
- Evaluate the commutability of PTH International standard PTH 95/646 and the need to create primary reference material
- Replicate the RMP in a second lab and create a network of 3-4 reference labs
- Create an accuracy-based external quality assessment scheme
- Constitute an appropriate and international panel of sera and plasma to establish PTH reference intervals
- Specify performance criteria for RMP and routine methods
- Provide services to manufacturers, notably by providing a reliable source for primary reference materials
- Post-survey of the standardization effects

### 2. Bone markers assays

- Continue the liaison with IOF and extend to other relevant international societies

### Current CTX and PINP project:

- Complete the multicenter study and harmonize CTX and PINP assays
- Collaborate with EQAS provider(s) to improve the surveys
- Constitute an appropriate and international panel of sera and plasma to establish CTX and PINP reference intervals
- Post-survey of the standardization/harmonization effects.

### Future projects:

- Select biomarkers to be standardized/harmonized (g.: bone alkaline phosphatase, FGF-23, sclerostin).


### 3. Vitamin D metabolites

- Re-evaluate current VDSP performance guidelines for 25(OH)D
- Establish VDSP performance guidelines for 24,25(OH)2D, C3-epimer and vitamin D binding protein
- Post-survey of the standardization effects
- Propose services to reassess the true value of 25OHD obtained in former epidemiological or interventional studies that had used non-standardized methods

Nominations should be sent directly to the IFCC Office ([paola.bramati@ifcc.org](mailto:paola.bramati@ifcc.org)) by using the enclosed application form, **before December 20<sup>th</sup>, 2022.**

Yours sincerely

Prof. Philippe Gillery, MD, PhD

A handwritten signature in black ink, appearing to be 'P. Gillery', written over a horizontal line.

Chair IFCC Scientific Division